Ascletis Pharma Inc. Advances Acne Treatment with Denifanstat
Ascletis Pharma Inc. has made significant strides in acne treatment with their innovative drug, denifanstat (ASC40). The results from a Phase III study were presented during the Late Breaking News sessions at the European Academy of Dermatology and Venereology (EADV) Congress. This first-in-class FASN inhibitor has shown remarkable efficacy in treating moderate to severe acne, outperforming placebo across all primary endpoints.
Efficacy of Denifanstat (ASC40) in Treating Acne
In the study, denifanstat met all primary, key secondary, and secondary efficacy endpoints, indicating a substantial improvement in acne conditions compared to the placebo group. The results highlighted that denifanstat effectively improved moderate-to-severe acne. The treatment produced a remarkable rate of success, as indicated by the Investigator's Global Assessment (IGA) scores. Patients receiving denifanstat displayed notable reductions in both total lesion count (TLC) and inflammatory lesion count (ILC).
Safety and Tolerability Profile
Denifanstat (ASC40) was well-tolerated among participants. The incidence of treatment-emergent adverse events (TEAEs) was comparable to placebo, with rates of 58.6% for denifanstat and 56.3% for the placebo. Most TEAEs were found to be mild or moderate, providing exciting insights into the safety of denifanstat as an acne treatment.
Presentation Highlights from EADV Congress
Dr. Leihong (Flora) XIANG, the principal investigator of the Phase III study, presented the findings. The trial evaluated 480 patients in a randomized, double-blind, placebo-controlled setup, administering 50 mg of denifanstat or a matching placebo once daily for 12 weeks. The efficacy endpoints revealed statistically and clinically significant improvements throughout the trial, confirming denifanstat's potential in modern dermatological care.
Detailed Study Results
After just four weeks, significant improvements were observed in the denifanstat group when compared to placebo across various efficacy endpoints. Notably, the treatment success rate marked a significant difference, with more favorable responses from patients on denifanstat.
Future Directions for Denifanstat
Ascletis is currently consulting with the China National Medical Products Administration (NMPA) about the next steps for denifanstat's approval. The company is encouraged by the feedback from NMPA and plans to submit a New Drug Application (NDA) for denifanstat aimed at addressing the challenges of moderate to severe acne vulgaris.
About Ascletis Pharma Inc.
Founded to confront metabolic diseases head-on, Ascletis harnesses advanced technologies, including its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform. They have positioned themselves at the forefront of drug development with a focus on achieving best-in-class therapies. Ascletis is listed on the Hong Kong Stock Exchange under the ticker 1672.HK.
Frequently Asked Questions
What is denifanstat (ASC40)?
Denifanstat (ASC40) is a first-in-class FASN inhibitor designed for the treatment of moderate to severe acne.
How effective is denifanstat in treating acne?
The Phase III study indicated that denifanstat significantly improved acne symptoms compared to placebo, with high treatment success rates.
What are the safety concerns related to denifanstat?
Denifanstat exhibited a favorable safety profile, with adverse effects primarily being mild to moderate and comparable to placebo.
When can we expect denifanstat to be available for patients?
Ascletis plans to submit a New Drug Application (NDA) and will continue to seek feedback from regulatory bodies to streamline the approval process.
How does Ascletis Pharma compare to others in the biotechnology industry?
Ascletis combines innovative drug discovery with a commitment to developing first-in-class treatments, aiming to lead in the biotechnology sector.
